Analysts Conflicted on These Healthcare Names: Hims & Hers Health (HIMS) and ACADIA Pharmaceuticals (ACAD)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report) and ACADIA Pharmaceuticals (ACAD – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hims & Hers Health (HIMS)
In a report released yesterday, David Larsen from BTIG maintained a Hold rating on Hims & Hers Health. The company’s shares closed last Thursday at $15.88, close to its 52-week low of $11.20.
According to TipRanks.com, Larsen has 0 stars on 0-5 stars ranking scale with an average return of
Hims & Hers Health has an analyst consensus of Hold, with a price target consensus of $26.57, implying a 60.7% upside from current levels. In a report issued on February 24, TipRanks – OpenAI also downgraded the stock to Hold with a $16.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
ACADIA Pharmaceuticals (ACAD)
Mizuho Securities analyst Uy Ear reiterated a Buy rating on ACADIA Pharmaceuticals yesterday and set a price target of $35.00. The company’s shares closed last Thursday at $22.40.
According to TipRanks.com, Ear is a 1-star analyst with an average return of
ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $32.53, which is a 42.2% upside from current levels. In a report released yesterday, TipRanks – OpenAI also upgraded the stock to Buy with a $26.00 price target.
